Description

Metoprolol & Ramipril Bilayer Tablets (25mg/2.5mg & 50mg/5mg)

Healthy Inc is a specialized global supplier and exporter of advanced cardiovascular, anti-hypertensive, and post-myocardial infarction therapeutics. We provide ultra-high-purity, kinetically synchronized Metoprolol (as Succinate ER/Tartrate) & Ramipril Film-Coated Bilayer Tablets (25mg/2.5mg & 50mg/5mg), manufactured in WHO–GMP certified, high-precision modified-release oral solid dosage facilities. This “Dual-Action Cardioprotective Synergy” is an ultra-high-value, highly lucrative export to cardiology centers, post-surgical recovery wards, retail pharmacy networks, and government health ministries in LATAM, the CIS, Africa, and Southeast Asia, serving as the globally mandated, life-saving intervention for Chronic Heart Failure, severe Essential Hypertension, and Post-Myocardial Infarction survival.

Product Overview

This highly advanced Fixed-Dose Combination (FDC) masterfully synchronizes an elite cardioselective beta-blocker with a heavy-hitting ACE inhibitor. Together, they form an impenetrable shield around a damaged or failing heart, profoundly extending patient lifespan.

The “Cardiac Shield & Anti-Remodeling” Specialist:

• Mechanism 1 (The Adrenaline Shield – Metoprolol): Metoprolol is a highly selective Beta-1 adrenergic blocker. Following a heart attack or in chronic heart failure, the body panics and floods the heart with adrenaline, whipping the damaged muscle to beat faster and harder. Metoprolol physically blocks these receptors, shielding the heart from toxic adrenaline, drastically slowing the resting heart rate, and preventing fatal arrhythmias.
• Mechanism 2 (The Anti-Remodeling Engine – Ramipril): Ramipril is a potent Angiotensin-Converting Enzyme (ACE) Inhibitor. It aggressively stops the body from producing Angiotensin II, a chemical that constricts blood vessels. More importantly, after a heart attack, the heart tries to “heal” itself by growing thick, stiff, and enlarged (pathological cardiac remodeling), eventually leading to complete failure. Ramipril directly halts and reverses this structural damage, keeping the heart muscle pliable and functional.
• The “Post-MI” Survival Advantage: Taking these two molecules separately leads to high rates of pill fatigue and therapy abandonment in elderly cardiovascular patients. By combining the rate-controlling power of a beta-blocker with the pressure-reducing and tissue-healing power of an ACE inhibitor into a single, once-daily tablet, clinical compliance skyrockets, directly preventing secondary, fatal heart attacks.

Product Composition & Strength

We supply this product as a Precision-Engineered, API-Segregated Bilayer Tablet, packed exclusively in highly secure, moisture-resistant Alu-Alu blister strips to ensure the absolute chemical stability of the highly degradable Ramipril molecule.

*Pack Sizes: 10×10 Alu-Alu Blisters (Optimized specifically for strict 30-day chronic cardiology dispensing regimens).

Technical & Logistics Specifications

Critical data for Pharmaceutical Importers, Cardiology Distributors, and Hospital Procurement Boards.

Manufacturing Authority

Marketed and Distributed by Healthy Inc from WHO-GMP & ISO 9001:2015 certified units.

• Alkaline Bilayer Segregation Engineering (CRITICAL COMPLIANCE): Ramipril is notoriously unstable under mechanical stress and humidity. If mixed haphazardly with Metoprolol in a single-layer matrix, the APIs will chemically attack each other. Our facilities utilize advanced, climate-controlled Bilayer Rotary Presses. We physically separate the two APIs into distinct layers within the same tablet, often incorporating precise polymeric stabilizers to buffer the micro-environment. This guarantees complete chemical isolation during shelf-life and flawless, synchronized dissolution in the gastrointestinal tract.

Therapeutic Indications (Human Use)

Indicated for the comprehensive, step-up management of severe cardiovascular disease:

• Post-Myocardial Infarction: Secondary prevention to reduce the risk of cardiovascular death and hospitalization for heart failure in patients who have survived an acute heart attack.
• Chronic Heart Failure: Treatment of symptomatic heart failure (NYHA Class II-IV) to improve survival and reduce disease progression.
• Essential Hypertension: Treatment of high blood pressure as substitution therapy in patients adequately controlled on individual products given concurrently at the same dose level.

Dosage & Administration

Recommended Dosage (Strictly as per Cardiologist Guidelines):

• Standard Adult Dosing: One tablet taken orally once daily.
• Administration: Can be taken with or without food. Tablets must be swallowed completely whole with water to preserve the bilayer matrix integrity.
• Abrupt Cessation Warning: Because this FDC contains a beta-blocker, therapy MUST NOT be stopped abruptly. Sudden discontinuation can trigger severe rebound hypertension, angina, or a fatal myocardial infarction.

Safety Warnings (CRITICAL Regulatory & Clinical Data):

• BLACK BOX WARNING (Fetal Toxicity): Like all drugs acting directly on the renin-angiotensin system (Ramipril), this FDC must be discontinued immediately upon detection of pregnancy, as it can cause profound injury and death to the developing fetus.
• The ACE Inhibitor Dry Cough: Ramipril prevents the breakdown of bradykinin in the lungs. In up to 10% of patients, this causes a severe, persistent, non-productive “tickle” dry cough. If the cough becomes intolerable, the drug must be switched to an ARB (like Telmisartan).
• Severe Bradycardia & Heart Block: Metoprolol significantly slows the heart. It is strictly contraindicated in patients with severe bradycardia (< 45 bpm), second or third-degree heart block, or cardiogenic shock.
• Hyperkalemia: Ramipril forces the body to retain potassium. Concurrent use of potassium-sparing diuretics (like Spironolactone) or potassium supplements can lead to fatal cardiac arrhythmias.

Global Export & Contract Manufacturing Services

Healthy Inc stands as a premier Pharmaceutical Exporter in India, dedicated to serving international Pharma Traders, Wholesalers, and Cardiology Networks. As a verified Medicine Supplier in Mumbai, we offer flexible Third Party Manufacturing (Contract Manufacturing) services for Advanced Cardiovascular and Bilayer FDC Formulations. Whether you are looking for a reliable Government Tender Supplier for heart failure clinics in Africa or a B2B Pharma Marketplace partner for Latin America, our logistics network ensures timely, secure delivery of highly stable, WHO-GMP certified products.